The risk of LTBI reactivation is further increased by the treatment with tumour-necrosis-factor-α- (TNFα-) blocking agents [2], which have been proven to be effective therapy in autoimmune conditions such as rheumatoid arthritis (RA), psoriasis and psoriasis arthritis (PsA), and ankylosing spondylitis. This evidence concerns the gene TNF and rheumatoid arthritis.